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Abstract
Background:  Previous studies showed that the human melanoma differentiation-
associated gene-7 (mda-7), also known as interleukin-24 (IL-24), has potent antitumor
activity against human and murine cancer cells. However, the majority of these studies
were limited to in vitro testing. In the present study, we investigated the antitumor
activity of mda-7/IL-24 against human ovarian cancer cells both in vitro and in vivo.
Results: In vitro, treatment of ovarian cancer cells with an adenoviral vector carrying
the mda-7 gene (Ad-mda7) resulted in inhibition of cell proliferation and induction of
cell cycle arrest, leading to apoptosis. We did not observe inhibitory activity in Ad-
mda7-treated normal cells. In vivo, treatment of subcutaneous tumor xenografts with
Ad-mda7 resulted in significant tumor growth inhibition when compared with that in
control groups (p < 0.001). Molecular analysis of ovarian tumor tissue lysates treated
with Ad-mda7 showed that MDA-7 protein expression was associated with activation
of the caspase cascade.
Conclusion: Our results show that treatment of ovarian cancer cells with mda-7/IL-24
results in growth suppression both in vitro and in vivo.
Background
Ovarian cancer is the second most common gynecological
malignancy in the United States and is the fifth leading
cause of death in women worldwide [1]. An estimated
25,000 women have been diagnosed with ovarian cancer
in 2005, and 50% of these patients have died of the dis-
ease. Despite advances in the treatment of ovarian cancer,
the overall long-term survival rate of this disease has not
improved significantly. Hence, developing and testing
new therapeutic agents and strategies for it are warranted.
The human melanoma differentiation-associated gene-7
(mda-7), also known as interleukin-24 (IL-24), encodes a
protein of 206 amino acids with a predicted molecular
mass of 23.8 kDa [2]. Gene transfer studies have demon-
strated that mda-7 exerts its antitumor activity in a spec-
trum of cancer cells via multiple cell-type-dependent
signaling pathways, resulting in apoptosis [2,3]. Recent in
vitro studies from our laboratory and those performed by
others showed that mda-7/IL-24 can suppress ovarian
cancer cell growth in vitro and is dependent on the Fas/
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FasL or stress activated p38 mitogen-activated protein
kinase (MAPK) pathway [4,5]. Additionally, investigators
have shown that an adenoviral vector carrying the mda-7
gene (Ad-mda7) radiosensitizes ovarian cancer cells in
vitro [6]. Although mda-7/IL-24 has displayed antitumor
activity against ovarian cancer cells in vitro, the docu-
mented evidence of this activity in vivo is limited.
In the present study, we investigated the antitumor prop-
erties of Ad-mda7 against human ovarian cancer cells
both in vitro and in vivo in a mouse model. We demon-
strated that Ad-mda7 selectively exerts its antitumor
effects against ovarian cancer cells, leading to suppression
of tumor growth in vivo.
Results
Ad-mda7 inhibits ovarian cancer cell proliferation, induces 
cell cycle arrest, and regulates signaling molecules 
associated with apoptosis
Prior to the start of our study, we determined the trans-
duction efficiency of an adenoviral vector carrying green
fluorescent protein in MDAH2774, OVCA420, and IOSE-
80 cells at different doses. We observed a dose-dependent
increase in transduction of both tumor and normal cells,
as more than 60% of the cells were transduced at 3000 vp/
cell (data not shown). Based on this result, we used Ad-luc
and Ad-mda7 at 3000 vp/cell in all subsequent experi-
ments.
Treatment of MDAH2774, OVCA420, and IOSE-80 cells
with Ad-mda7 resulted in exogenous MDA-7 protein
expression that was detectable as multiple species on days
1, 2, and 3 after treatment (Figure 1). Detection of multi-
ple species of MDA-7 protein in Ad-mda7-treated cells
reflects glycosylated forms of the protein and in different
stages of glycosylation. MDA-7 being a glycosylated pro-
tein has previously been reported [2,4,8]. MDA-7 protein
expression was not detectable in cells treated with PBS or
Ad-luc. To determine the effects of treatment with Ad-
mda7 on cell proliferation, we treated cells with Ad-mda7
and examined them for the number of viable cells on days
3 and 5 after treatment. We observed significant inhibi-
tion of cell proliferation in Ad-mda7-treated ovarian can-
cer cells but not in PBS-treated or Ad-luc-treated cancer
cells (p = 0.001; Figure 2). Also, we did not observe a sig-
nificant inhibitory effect on cell proliferation in Ad-mda7-
treated normal cells when compared with PBS-treated or
Ad-luc-treated cells. These results showed that treatment
with Ad-mda7 results in exogenous MDA-7 protein
expression in both ovarian cancer and normal ovarian
epithelial cells. However, MDA-7 selectively inhibits
tumor-cell proliferation and minimally inhibits normal-
cell proliferation. Our results concur with findings previ-
ously reported by us and others [2,3,7].
Previous studies from our laboratory and others showed
mda-7/IL-24 inhibit human tumor cell proliferation by
inducing cell cycle arrest at G2/M phase [2-8]. Based on
these reports, we analyzed the effects of Ad-mda7 on the
cell cycle at 72 h after treatment. Treatment of both ovar-
ian cancer and normal cells with Ad-mda7 resulted in an
increase in the number of cells at G2/M phase (Table 1).
However, the number of cells at this phase was markedly
higher in the cancer cells (50.2% and 29% of MDAH2774
cells and OVCA420 cells, respectively) than in normal
cells (23%). Also, the number of Ad-luc-treated cancer
cells was higher than that of PBS-treated cancer cells at
G2/M phase. However, we did not observe a significantly
higher number of Ad-luc-treated normal cells than PBS-
treated normal cells at G2/M phase.
Previous studies also showed that cell signaling markers
such as PKR, p38MAPK, and pJNK are activated in Ad-
mda7-treated lung cancer and melanoma cell lines and
play a role in cell death [9-11]. Specifically, in the lung
cancer cell lines A549 and H1299, PKR and pJNK were
required for Ad-mda7-mediated cell killing [9,10],
whereas in the melanoma cell line MeWo, p38MAPK was
required for Ad-mda7-mediated cell killing [17]. Based on
these reports, we analyzed for the effect of Ad-mda7-treat-
ment on the expression levels of PKR, p38MAPk and pJNK
using Western blotting. Analysis of cell lysates collected at
72 h after treatment showed increased PKR, p38MAPK,
and pJNK expression in Ad-mda7-treated ovarian cancer
cells but not in PBS-treated or Ad-luc-treated cancer cells
(Figure 3). However, we did not observe increased activa-
tion of these molecular markers in Ad-mda7-treated nor-
mal cells when compared with that in PBS-treated or Ad-
luc-treated normal cells.
Because the previous studies described above showed that
PKR, pJNK, and p38MAPK play a role in Ad-mda7-medi-
ated cell-death and because we found that these markers
were activated in Ad-mda7-treated ovarian cancer cells, we
next analyzed caspase-3, caspase-9, and PARP, all of
which are downstream of PKR, p38MAPK, and pJNK, to
determine whether they are activated in apoptotic cells.
We observed induction of apoptosis as evidenced by acti-
vation of caspase-3 and caspase-9 and cleavage of PARP in
Ad-mda7-treated MDAH2774 and OVCA420 cells but not
in Ad-mda7-treated IOSE-80 cells (Figure 4). We also
observed a slight increase in caspase-3 and caspase-9 acti-
vation and PARP cleavage in Ad-luc-treated MDAH2774
cells compared with that in PBS-treated MDAH2774 cells.
However, we did not observe activation of these molecu-
lar markers in PBS-treated or Ad-luc-treated OVCA420 or
IOSE-80 cells. These results show that Ad-mda7 inhibits
ovarian cancer cell proliferation by inducing cell cycle
arrest at G2/M phase and activates several cell signaling
molecules associated with apoptosis, resulting in cellMolecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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death. However, Ad-mda7-mediated inhibitory activity
appears to be reduced or absent in normal cells. The abil-
ity of Ad-mda7 to selectively inhibit tumor cells and not
normal cells agrees with findings of our previous studies
[2,8,12].
Ad-mda7 inhibits ovarian tumor xenografts in vivo
Previous studies from our laboratory showed that intratu-
moral administration of Ad-mda7 inhibits the growth of
lung tumor xenografts [13,14]. Additionally, we showed
that systemic nanoparticle-based delivery of mda-7 inhib-
its experimental lung metastasis [14]. Based on these
reports and our present observation of the ability of Ad-
mda7 to inhibit ovarian tumor cell proliferation in vitro,
we tested the growth inhibitory effects of Ad-mda7 in vivo
Intratumoral administration of Ad-mda7 in mice bearing
subcutaneous tumors formed after injection of
MDAH2774 cells subcutaneous MDAH2774 tumors
resulted in significant tumor-growth inhibition when
compared with intratumoral administration of PBS or Ad-
luc (p < 0.05; Figure 5). Growth inhibition began on day
18 after initiation of treatment and continued until day
32, at which time we stopped the study. We did not
observe significant tumor inhibition in Ad-luc-treated
mice compared with that in PBS-treated mice.
Analysis of ovarian tumor tissue lysates showed that the
growth inhibition we observed in Ad-mda7-treated mice
was caused by MDA-7 protein expression. Specifically,
Western blot analysis showed exogenous MDA-7 protein
MDA-7 protein detection in Ad-mda7-treated cells Figure 1
MDA-7 protein detection in Ad-mda7-treated cells. MDAH2774, OVCA420, and IOSE-80 cells treated with PBS, Ad-Luc, or 
Ad-mda7 were harvested at days 1, 2, and 3 after treatment and analyzed for exogenous MDA-7 protein expression by west-
ern blotting. MDA-7 expression was detected in Ad-mda7-treated cells but not in PBS-treated or Ad-luc-treated cells. β-actin 
was used as an internal loading control.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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expression in Ad-mda7-treated tumor tissue lysates as evi-
denced by intense protein banding (Figure 6). We
detected some protein banding, albeit at baseline levels,
corresponding to MDA-7 protein expression in PBS-
treated and Ad-luc-treated tumor lysates. Because in vitro
studies did not show endogenous MDA-7 protein expres-
sion in MDAH2774 cells, we believe that the protein
banding seen in the control lysates was probably nonspe-
Table 1: Cell cycle distribution in ovarian cancer and normal cells treated with PBS, Ad-luc or Ad-mda7
MDAH 2774 (%) OVCA 420 (%) IOSE 80 (%)
G1 S G2M G1 S G2M G1 S G2M
PBS 72.2 ± 10.5 20.4 ± 9.3 7.3 ± 1.5 68.2 ± 4.9 21.7 ± 5.2 10.0 ± 1.6 40.2 ± 1.4 42.0 ± 2.6 18.0 ± 1.6
Ad-Luc 52.5 ± 6.2 25.2 ± 3.0 22.2 ± 3.3 68.2 ± 6.3 13.1 ± 2.3 18.2 ± 4.6 55.3 ± 2.2 26.3 ± 1.2 19.0 ± 1.5
Ad-mda7 243 ± 38 27.0 ± 14.6 50.2 ± 16.4 57.0 ± 4.8 14.4 ± 2.4 29.0 ± 4.2 48.8 ± 3.6 28.6 ± 2.1 23.0 ± 2.5
NOTE: Cells were treated with PBS, Ad-luc or Ad-mda7 for 72 hours followed by FACS analysis. The percentage of cells In each cell cycle phase 
was determined by analysis of the DMA content. Values are the means of duplicate experiments ± SD.
Ad-mda7 inhibits tumor cell proliferation Figure 2
Ad-mda7 inhibits tumor cell proliferation. MDAH2774, OVCA420, and IOSE-80 cells treated with PBS, Ad-Luc, or Ad-mda7 
were harvested at days 3, and 5 after treatment and analyzed for cell proliferation. Proliferation of tumor cells but not normal 
cells treated with Ad-mda7 was significantly lower (p = 0.001) than that of cells treated with PBS or Ad-Luc. Error bars denote 
standard error.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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cific bands that are reacting to the polyclonal antibody
against MDA-7. An alternate explanation is that the MDA-
7 antibody also detects mouse MDA-7 protein expression,
because the subcutaneous tumor xenograft grown in mice
comprised of the human ovarian cancer cells intermixed
with host cells, including fibroblasts, stromal cells, and
endothelial cells. We are currently studying these possibil-
ities in our laboratory.
We also found that MDA-7 protein expression was associ-
ated with detection of decreased procaspase-3, procas-
pase-9, and PARP expression in Ad-mda7-treated tumor
tissue lysates compared to expression levels of these mark-
ers in PBS-treated tumor tissue lysates (Figure 7). Surpris-
ingly, we observed lower expression of these markers in
Ad-luc-treated tumor tissue lysates than in PBS-treated
lysates. However, the decrease, at least for procaspase-3
and procaspase-9, was greater in Ad-mda7-treated lysates
than in Ad-luc-treated lysates. Thus, our in vivo results
showed that Ad-mda7 can effectively inhibit ovarian
tumor growth and induce apoptosis similar to that
observed in our in vitro studies.
Discussion
In the present study we investigated the antitumor activity
of mda-7/IL-24 against human ovarian cancer cells and
compared to normal ovarian epithelial cells in vitro and
the mda-7-mediated growth inhibitory effects on human
ovarian tumor xenograft mouse models in vivo. For this
purpose we used an adenoviral vector carrying the mda-7
gene (Ad-mda7). In vitro studies showed Ad-mda7 selec-
tively inhibited the growth of ovarian tumor cells but not
normal ovarian epithelial cells. Associated with Ad-mda7-
mediated growth inhibition was the marked increase in
the number of tumor cells in the G2/M phase of cell cycle
indicating cell cycle arrest. The ability of Ad-mda7 to
selectively inhibit ovarian tumor cell growth in the G2/M
phase with no effect on normal cells concurs with our pre-
vious reports on the inhibitory effects of mda-7 on other
human tumor cell types [2,4,8,12,15].
Studies in lung cancer and melanoma have previously
shown Ad-mda7-mediated tumor cell death occurs by
activation of PKR, p38MAPK and pJNK leading to activa-
tion of the caspase cascade [7,9-11]. Analysis for activa-
tion of these molecular markers in the present study
showed increased PKR, p38MAPK and pJNK expression in
Ad-mda7-treated ovarian tumor cells but not in normal
cells. Furthermore, activation of caspase-9, -3 and PARP
was also observed in Ad-mda7-treated ovarian tumor cells
but not in normal cells. Our results show that Ad-mda7
induces cell death of ovarian cancer cells by activation of
the cell death signaling pathways, an observation that has
not previously been reported for ovarian cancer.
Since in vitro results do not always correlated with in vivo
studies, we investigated the growth inhibitory effects of
Ad-mda7 using ovarian tumor xenografts established in
nude mice. We observed Ad-mda7 significantly inhibited
the growth of subcutaneous MDAH2774 tumors. MDA-7-
mediated growth inhibition in vivo correlated with activa-
tion of molecular markers such as caspases that was also
observed in vitro in Ad-mda7-treated tumor cells. The abil-
ity of Ad-mda7 to inhibit the growth of ovarian tumor
xenografts is not surprising and concurs with our previous
findings on lung tumor xenografts [13]. However, the Ad-
Ad-mda7 activates molecular markers associated with cell killing Figure 3
Ad-mda7 activates molecular markers associated with cell killing. Western blot analysis showed activation of PKR, p38MAPK, 
and pJNK in Ad-mda7-treated tumor cells but not in PBS-treated or Ad-luc-treated tumor cells. We did not observe activation 
of these markers in normal cells treated with PBS, Ad-luc, or Ad-mda7. β-actin was used as an internal loading control.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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mda7-mediated inhibitory effect on ovarian tumors
observed in the present study was more significant than
that observed previously in lung tumor xenografts [13].
Although we showed in this study that mda-7 gene deliv-
ery using an adenoviral vector can inhibit subcutaneous
ovarian tumor growth and established a proof of concept,
the reality is that ovarian tumors grow inside the abdo-
men, so the therapeutic effect of Ad-mda7 must be tested
in an intraperitoneal tumor model. However, reports have
shown that ovarian tumor cells growing in the peritoneal
cavity are not efficiently infected with adenoviral vectors
carrying therapeutic genes for several reasons, including
low surface expression of the adenoviral receptors by
tumor cells, interference between the adenovirus and
tumor cells by ascitic fluid, rapid clearance of the adeno-
virus, and induction of host immunity against the viral
proteins [16,17]. To overcome some of these limitations,
investigators have used targeting strategies that have
shown limited success [18,19]. A recent study by Mahas-
reshti et al. [5] showed that targeted Ad-mda7 delivery can
inhibit ovarian cancer growth and prolong the duration of
animal survival when compared with that using a nontar-
geted adenoviral vector carrying the mda-7 gene. How-
ever, in that study, the animals received treatment only
twice, raising the possibility that when administered
repeatedly, a targeted adenoviral vector can become inef-
fective because of clearance of it by the host immune sys-
tem. Additionally, in the same study, the researchers
administered mda-7 to tumor-bearing mice at earlier time
points (days 2 and 14 after tumor cell inoculation) at
which time there may not have been enough ascitic fluid
to interfere with adenoviral infection.
Based on these reports demonstrating the potential prob-
lems of using adenovirus-based therapy for ovarian can-
cer, an alternate is the use of lipid-based nanoparticles for
the treatment of intraperitoneal ovarian tumor-bearing
mice. The rationale for testing nanoparticle-based mda-7
therapy are that they are less immunogenic and stable for
extended periods of time (6-24 h) in vivo compared to
adenovirus-based therapy. Furthermore, studies from our
laboratory have shown that the lipid-based nanoparticles
are effective gene delivery vehicles when administered sys-
temically [14,15]. We in the laboratory are currently test-
ing the antitumor properties of mda-7 contained in lipid-
based nanoparticles for the treatment of intraperitoneal
ovarian tumor-bearing mice. It is anticipated that these
studies will provide a basis for future preclinical studies.
Conclusion
Our study demonstrates Ad-mda7 can selectively and
effectively inhibit ovarian cancer both in vitro and in vivo
and is therapeutic agent for ovarian cancer. However,
Ad-mda7 activates the caspase cascade in tumor cells Figure 4
Ad-mda7 activates the caspase cascade in tumor cells. Activation of caspase-9, caspase-3 and PARP indicated by their cleavage 
products was observed in Ad-mda7-treated tumor cells but not in Ad-mda7-treated normal cells. β-actin was used as a loading 
control.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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delivery of mda-7 using alternate gene delivery vector sys-
tems such as nanoparticles is required to achieve effective
control of ovarian tumor growth in the abdominal cavity.
Methods
Cell lines and cell culture
The human ovarian cancer cell lines MDAH2774 and
OVCA420 were grown as described previously [20]. IOSE-
80 human normal ovarian epithelial cells were provided
by Dr Gordon Mills (The University of Texas M. D. Ander-
son Cancer Center, Houston, TX).
Adenovirus vector
The replication-defective Ad-mda7 vector was constructed
and purified as previously described [8,13]. Briefly, repli-
cation-deficient human type 5 adenoviral vectors were
constructed to express either mda-7 (Ad-mda7) or luci-
ferase (Ad-luc) genes linked to an internal cytomegalovi-
rus immediated-early promoter and followed by an SV40
polyadenylation signal. The viruses were propagated in
HEK293 human embryonic kidney cells and purified by
column chromatography.
Cell viability and cell cycle assay
Tumor and normal cells (105) treated with phosphate-
buffered saline (PBS), an adenoviral vector carrying the
Ad-mda7 inhibits growth of ovarian tumor xenografts in vivo Figure 5
Ad-mda7 inhibits growth of ovarian tumor xenografts in vivo. Subcutaneous ovarian tumors formed after injection of 
MDAH2774 cells were treated with PBS, Ad-luc, or Ad-mda7 and measured tumor growth using calipers. A significant inhibi-
tion of tumor growth was observed in Ad-mda7-treated tumors but not in PBS-treated or Ad-luc-treated tumors. The arrows 
indicate when treatment was administered. *Significance.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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luciferase gene (Ad-luc), or Ad-mda7 (3000 vp/cell) were
subjected to cell viability and cell cycle analysis as
described previously [8,12,13]. Cell viability analysis was
performed on day 3 and day 5 after treatment, whereas
cell cycle analysis was performed on day 3 after treatment.
Treatment was performed in triplicate, and experiments
were repeated at least twice to ensure reproducibility and
statistical significance. The results presented are represent-
ative of one experiment.
Western blot analysis
Tumor and normal cells (105) treated with PBS, Ad-luc, or
Ad-mda7 were harvested at 24, 48, and 72 h after treat-
ment and subjected to Western blotting [8,12,13]. The fol-
lowing primary antibodies were used in the Western blot
analysis: total double-stranded RNA-dependent protein
kinase (PKR), p38MAPK, phospho-specific c-Jun N-termi-
nal kinase (pJNK), and caspase-9 (Cell Signaling, Boston,
MA); caspase-3, poly(ADP-ribose) polymerase (PARP),
and β-actin (Sigma Chemical Co., St. Louis, MO); and
MDA-7 (Introgen Therapeutics, Inc., Houston, TX).
In vivo studies
Female athymic BALB/c female nude mice of 4–6 weeks
age were purchased from Charles River Laboratories
(Willimington, MA). Mice were housed in sterile patho-
gen free environment and fed ad libitum.
Prior to start of the experiment mice were subjected to
whole body cesium radiation (350 rads) to enhance
uptake of human xenograft tumor cells. Twenty-four after
radiation the mice were injected with MDAH2774 tumor
cells (5 × 106) subcutaneously into the lower right flank (n
= 18). The mice were separated into groups by treatment
(six each for PBS, Ad-luc, and Ad-mda7) and administered
treatment when their tumors reached 40 to 50 mm3 in
volume. Treatments were administered intratumorally for
all groups on days 1, 3, 5, 7, 17, 20, 24, 26, and 32. Ad-luc
and Ad-mda7 doses administered were 5 × 109 vp/dose.
Tumor growth was measured two to three times per week
as described previously [13,15]. The animals were killed
by CO2 inhalation at the end of the experiment per insti-
tutional approved guidelines. The experiments were car-
ried out twice; data from one representative study are
presented. All of the in vivo studies conducted were
approved by the institutional animal care and welfare
committee and performed according to N.I.H. guidelines.
For molecular analysis of MDA-7, procaspase-3, procas-
pase-9, and PARP expression in Ad-mda7-treated tumor
tissues, subcutaneous ovarian tumor tissue samples were
harvested from mice upon termination of the study and
snap-frozen in dry ice. Samples were subsequently ground
using a homogenizer, and tissue lysates were prepared
and analyzed for expression of the indicated molecular
Ad-mda7-mediated tumor growth inhibition is due to MDA-7 protein expression Figure 6
Ad-mda7-mediated tumor growth inhibition is due to MDA-7 protein expression. Tissue lysates prepared from PBS-treated, 
Ad-luc-treated, and Ad-mda7-treated subcutaneous tumors were subjected to western blotting and detected for MDA-7 pro-
tein. Exogenous MDA-7 protein expression was detected in Ad-mda7-treated tumor tissue lysates but not PBS-treated tumor 
lysates. A non-specific band in one sample of Ad-luc-treated tumor lysate was observed. β-actin was used as a loading control.Molecular Cancer 2007, 6:11 http://www.molecular-cancer.com/content/6/1/11
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markers using Western blot analysis as described previ-
ously [21].
Statistical analysis
All of the experiments were performed twice, and experi-
mental results were analyzed for statistical significance
using Student's t-test and analysis of variance. Values of p
< 0.05 were considered statistically significant.
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